ANTX
NASDAQ
US
AN2 Therapeutics, Inc. - Common Stock
$3,27
▼ $-0,18
(-5,22%)
Vol. 412K
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$31.2M
ROE
-47,8%
D/E
0,00
Beta
-0,02
52W
$1–$2
Consenso Wall Street
6 analisti · Apr 20260
Acquisto forte
0
Compra
3
Mantieni
1
Vendi
2
Vendita forte
0,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
ORMP
Oramed Pharmaceuticals Inc
P/E 2,6
$113.4M
NTHI
NeOnc Technologies Holdings Inc
$198.2M
DERM
Journey Medical Corp
$209.2M
ASRT
Assertio Holdings Inc
$58.2M
LONA
LeonaBio Inc
TTRX
Turn Therapeutics Inc
VRCA
Verrica Pharmaceuticals Inc
$78.9M
AARD
Aardvark Therapeutics Inc
$285.8M
RANI
Rani Therapeutics Holdings Inc
$164.1M
Utili
Tasso di battuta: 40,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,24 | $-0,29 | $-0,05 |
| Set 2025 | $-0,22 | $-0,31 | $-0,09 |
| Giu 2025 | $-0,34 | $-0,21 | +$0,13 |
| Mar 2025 | $-0,26 | $-0,35 | $-0,09 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$12.7M | -$7.5M | -$10.6M | -$6.5M | -$9.4M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -48.2% | -48.0% | -48.0% | -48.0% | -47.8% | -47.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.67 | 9.67 | 9.67 | 9.67 | 9.33 | 9.33 |
Rapporti chiave
ROA (TTM)
-43,0%
P/B
0,5
EPS (TTM)
$-1,13
52W High
$1,55
52W Low
$1,01
$1,01
Intervallo 52 settimane
$1,55
Salute finanziaria
Flusso di cassa libero
-$6.4M
Liquidità
$18.0M
Aggiornato al Set 30, 2025
Як ANTX виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ANTX vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(5,0)
vs Peer
vs Settore
Sopravvalutato
P/B
0,5
▼
76%
sotto
peer
(2,1)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ANTX vs аналоги Pharmaceuticals
ROE
-47,8%
▲
12%
sopra
peer
(-54,3%)
vs Peer
vs Settore
In linea
Net margin
—
▼
0%
sotto
peer
(-47,4%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(68,3%)
vs Peer
vs Settore
In linea
ROA
-43,0%
▼
15%
sotto
peer
(-37,4%)
vs Peer
vs Settore
In linea
Фінансове здоровʼя ANTX vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
sotto
peer
(1,5)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
9,3
▲
178%
sopra
peer
(3,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,0
▼
103%
sotto
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ANTX
ANTX
Mediana peer
Industria
ANTX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ANTX vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
CHANDA SANJAY
Officer · Feb 20
38000 shs
DAY LUCY O.
Chief Financial Officer · Feb 20
38000 shs
EASOM ERIC
Chief Executive Officer · Feb 20
112250 shs
EIZEN JOSHUA M
Chief Operating Officer · Feb 20
50000 shs
MARKS GILBERT LYNN
Director · Gen 12
11560 shs
MARTIN PATRICIA A
Director · Gen 12
3650 shs
AZIZ KABEER
Director · Gen 12
11560 shs
CHANDA SANJAY
Officer · Gen 06
9251 shs
DAY LUCY O.
Chief Financial Officer · Gen 06
8807 shs
EIZEN JOSHUA M
Officer · Gen 06
24854 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 12,52%Almitas Capital LLC
4,12%
$5.4M
Vanguard Group Inc
3,01%
$4.0M
Pfizer Inc
1,99%
$2.6M
Stonepine Capital Managemen…
1,75%
$2.3M
Peapod Lane Capital LLC …
1,65%
$2.2M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora